http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 13:50:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Milestone+Pharmaceutical+++++++++++++++Filed+by%3A+Pavaki+Capital+Management+LLC/26890186.html si-local-file:///var/storage/secattach/20260807/26890186.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Milestone+Pharmaceutical+++++++++++++++Filed+by%3A+Pavaki+Capital+Management+LLC/26890186.html Fri, 07 Aug 2026 13:50:00 -0400 MIST O.07505859 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Milestone+Pharmaceutical+++++++++++++++Filed+by%3A+Pavaki+Capital+Management+LLC/26890186.html si-local-file:///var/storage/secattach/20260807/26890186.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Milestone+Pharmaceutical+++++++++++++++Filed+by%3A+Pavaki+Capital+Management+LLC/26890186.html Fri, 07 Aug 2026 13:50:00 -0400 MIST O.07505859 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9QgbL348kdYsd4fkEsJqf3I6KO8JEE--p5XMWseDRo4upVHH7S-dOW494cXW_fXNTvDPPfRaNLgwNuj3RaaeMTyyKlLmT8CatLpHwJKETEI6d7pgtbct4N17tWNj1-LbSh63R6qUPye7pmJOJDZiWg==" rel="nofollow" target="_blank">here</a>.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:30%; width:30%; min-width:30%;"><strong>Conference Details:</strong></td><td http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html Tue, 04 Aug 2026 16:01:00 -0400 MIST O.07505859 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9QgbL348kdYsd4fkEsJqf3I6KO8JEE--p5XMWseDRo4upVHH7S-dOW494cXW_fXNTvDPPfRaNLgwNuj3RaaeMTyyKlLmT8CatLpHwJKETEI6d7pgtbct4N17tWNj1-LbSh63R6qUPye7pmJOJDZiWg==" rel="nofollow" target="_blank">here</a>.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:30%; width:30%; min-width:30%;"><strong>Conference Details:</strong></td><td http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html Tue, 04 Aug 2026 16:01:00 -0400 MIST O.07505859 http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9QgbL348kdYsd4fkEsJqf3I6KO8JEE--p5XMWseDRo4upVHH7S-dOW494cXW_fXNTvDPPfRaNLgwNuj3RaaeMTyyKlLmT8CatLpHwJKETEI6d7pgtbct4N17tWNj1-LbSh63R6qUPye7pmJOJDZiWg==" rel="nofollow" target="_blank">here</a>.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:30%; width:30%; min-width:30%;"><strong>Conference Details:</strong></td><td http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html Tue, 04 Aug 2026 16:01:00 -0400 MIST O.07505859 http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9QgbL348kdYsd4fkEsJqf3I6KO8JEE--p5XMWseDRo4upVHH7S-dOW494cXW_fXNTvDPPfRaNLgwNuj3RaaeMTyyKlLmT8CatLpHwJKETEI6d7pgtbct4N17tWNj1-LbSh63R6qUPye7pmJOJDZiWg==" rel="nofollow" target="_blank">here</a>.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:30%; width:30%; min-width:30%;"><strong>Conference Details:</strong></td><td http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26865805.html Tue, 04 Aug 2026 16:01:00 -0400 MIST O.07505859 http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html <p align="justify">MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees. </p> <p align="justify">The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html Thu, 02 Jul 2026 21:30:00 -0400 MIST O.07505859 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html <p align="justify">MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees. </p> <p align="justify">The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html Thu, 02 Jul 2026 21:30:00 -0400 MIST O.07505859 http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html <p align="justify">MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees. </p> <p align="justify">The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html Thu, 02 Jul 2026 21:30:00 -0400 MIST O.07505859 http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html <p align="justify">MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees. </p> <p align="justify">The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26730286.html Thu, 02 Jul 2026 21:30:00 -0400 MIST O.07505859 http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html <p>Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.</p> <p>Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.</p> <p>His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html Tue, 23 Jun 2026 08:30:38 -0400 A.34829763 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html <p>Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.</p> <p>Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.</p> <p>His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html Tue, 23 Jun 2026 08:30:38 -0400 A.34829763 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html <p>Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.</p> <p>Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.</p> <p>His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html Tue, 23 Jun 2026 08:30:38 -0400 A.34829763 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html <p>Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.</p> <p>Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.</p> <p>His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html Tue, 23 Jun 2026 08:30:38 -0400 A.34829763 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html <p>Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.</p> <p>Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.</p> <p>His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html Tue, 23 Jun 2026 08:30:38 -0400 A.34829763 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html <p>Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.</p> <p>Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.</p> <p>His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html Tue, 23 Jun 2026 08:30:38 -0400 A.34829763 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html <p>Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.</p> <p>Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.</p> <p>His prior board roles include Chairman of CymaBay Therapeutics (Nasdaq: CBAY) before its acquisition by http://www.streetinsider.com/Board+Changes/Alpha+Cognition+names+Dr.+Robert+Wills+as+board+chairman/26676443.html Tue, 23 Jun 2026 08:30:38 -0400 A.34829763 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT